Emcure Pharmaceuticals Ltd IPO
Open Demat Account
Emcure Pharmaceuticals Ltd IPO Details
Details
Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
---|---|---|---|---|---|
₹ 193.65 L | ₹ 114.29 L | ₹ 67.4 L | ₹ 985.91 L | BSE | ₹ 1952.03 Cr |
IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
03 Jul, 24 | 05 Jul, 24 | 14 | ₹ 13,440 | Book Building | 10 Jul, 24 |
Emcure Pharmaceuticals Ltd IPO Dates
Details
Sector | Type |
---|---|
Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
Sub Sector | NA |
Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
---|---|---|---|
QIB | 76.53x | 9628224 | 736891932 |
NII | 49.34x | 2888467 | 142526748 |
Retail | 7.36x | 6739756 | 49618982 |
Employee | 8.81x | 108900 | 959728 |
Total | 48.02x | 19365347 | 929997390 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Emcure Pharmaceuticals Ltd Financial Status
Income Statement
Balance Sheet
Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
---|---|---|---|
Revenue from operations | 390.86 | 782.22 | 712.11 |
EBITDA | 569.38 | 948.01 | 866.32 |
PAT | 160.06 | 446.81 | 420.48 |
Total Assets | 2,159.41 | 2,141.63 | 2,252.79 |
Share Capital | 180.85 | 180.85 | 180.85 |
Total Borrowings | 1,921.72 | 1,933.03 | 1,670.38 |
Operating Activities (Net Cash) | 338.58 | 612.60 | 574.69 |
Investing Activities (Net Cash) | 436.92 | 324.11 | 671.64 |
Financing Activities (Net Cash) | 1,921.72 | 1,933.03 | 1,670.38 |
Net Cashflow | 141.02 | 47.88 | 260.73 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. The Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of the Company and the certificate of incorporation of the Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, the Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of the Company was changed to `Emcure Pharmaceuticals Limited', pursuant to its Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.
The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately US$1,900 billion (approximately Rs.157 trillion) to US$1,950 billion (approximately Rs.161 trillion) in the calendar year 2028. The Indian domestic formulations segment (consumption) is expected to grow at a CAGR of approximately 8% to 9% between the Financial Years 2024 and 2029, to reach approximately Rs.2.9 trillion to Rs.3.0 trillion in the Financial Year 2029, aided by strong demand from the rising incidence of chronic diseases, increased awareness and access to quality healthcare.
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company is a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, it is present across acute and chronic therapeutic areas, and its key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.
Peer Comparison:
- Dr Reddy's Laboratories Ltd
- Cipla Ltd
- Alkem Laboratories Ltd
- Torrent Pharmaceuticals Ltd
- Mankind Pharma Ltd
- Abbott India Ltd
- J B Chemicals & Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd IPO Key Points
Strengths
- Well-placed to leverage leading position in the domestic market.
- Demonstrated capabilities of building brands.
- Large, diversified and fast-growing product portfolio in international markets.
- Strong R&D capabilities driving differentiated portfolio of products.
- Extensive and diversified manufacturing capacity.
Risk
- Any manufacturing or quality control problems may damage its reputation, subject it to regulatory action, and expose it to litigation or other liabilities, which could adversely affect the company reputation, business, financial condition and results of operations.
- Its failures to comply with applicable quality standards may result in product liability claims, which could adversely affect its business, financial condition, cash flows and results of operations.
- Its manufacturing and research and development operations are subject to operational risks. Any slowdown or shutdown in its manufacturing or research and development operations could adversely affect its business, financial condition and results of operations.
Strategy
- Increase its Market Share in the Domestic Market.
- Continue to Invest in Research & Development and Manufacturing Capabilities to Enhance and Grow our Differentiated Product Portfolio.
- Deepen and Expand its International Presence with a Focused Go-to-Market Approach.
- Pursue Strategic Acquisitions, Partnerships and In-Licensing Arrangements.
- Well-placed to leverage leading position in the domestic market.
- Demonstrated capabilities of building brands.
- Large, diversified and fast-growing product portfolio in international markets.
- Strong R&D capabilities driving differentiated portfolio of products.
- Extensive and diversified manufacturing capacity.
How To Apply for Emcure Pharmaceuticals Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.